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The clinical suspicion of local recurrence of prostate cancer after radical treatment is based on the onset of biochemical failure. The use of
multiparametric magnetic resonance imaging (MRI) for prostate cancer has increased over recent years, mainly for detection, staging, and
active surveillance. However, suspicion of recurrence in the set of biochemical failure is becoming a significant reason for clinicians to
request multiparametric MRI. Radiologists should be able to recognize the normal posttreatment MRI findings. Fibrosis and atrophic
remnant seminal vesicles (SV) after radical prostatectomy are often found and must be differentiated from local relapse. Moreover,
brachytherapy, external beam radiotherapy, and focal therapies tend to diffusely decrease the signal intensity of the peripheral zone on
T2-weighted images due to the loss of water content, consequently mimicking tumor and hemorrhage. The combination of T2-weighted
images and functional studies like diffusion-weighted imaging and dynamic contrast-enhanced imaging improves the identification of local
relapse. Tumor recurrence tends to restrict on diffusion images and avidly enhances after contrast administration. The authors provide a
review of the normal findings and the signs of local tumor relapse after radical prostatectomy, external beam radiotherapy, brachytherapy
and focal therapies. r 2016 Elsevier Inc. All rights reserved.
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Multiparametric magnetic resonance imaging (mp-MRI)
has been used for detection, localization, and staging of
prostate cancer (PCa) over the last few years. It combines
T1-weighted images (T1WI) and T2-weighted images
(T2WI) with at least 2 functional techniques such as
dynamic contrast-enhanced imaging (DCEI), diffusion-
weighted imaging (DWI), and MR spectroscopy (MRS)
[1]. The role of mp-MRI on PCa has, however, been
extended to cases of active surveillance, patients who
refused biopsy, MRI-guided or MRI-Ultrasound fusion
biopsy, posttreatment surveillance, and diagnosis of recur-
rence after treatment [2]. Radical prostatectomy (RP) and
radiotherapy (RT), either by external beam radiotherapy.urolonc.2016.01.004
ier Inc. All rights reserved.
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.panebianco@uniroma1.it (V. Panebianco).(EBRT) or brachytherapy (BT), have curative intent in
patients with localized PCa. Other alternative treatment
options like focal ablative therapies are minimally invasive
procedures with reduced toxicity. However, they are not
completely established yet [3]. The aim of this article is to
review the fundamentals of mp-MRI in the setting of
biochemical recurrence (BR) after primary treatment. More-
over the authors provide an overview of the currently
available data concerning this new imaging technology on
the normal findings and the signs of local tumor relapse
after RP, EBRT, BT and focal therapies.Imaging approach to biochemical failure
Recurrence PCa after curative intent treatment is not
uncommon. Among patients undergoing RP or RT, 27%
to 53% develop biochemical failure (BF), which is defined
as a rise in prostate-specific antigen (PSA) level, and 16%
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differs between RP and RT. After RP, it is defined by 2
consecutive PSA values of 40.2 ng/ml. After RT, with or
without short-term hormonal manipulation, it is defined by
a PSA increase 42 ng/ml higher than the initial PSA nadir
value [4,5]. However, it must be stressed that some poorly
differentiated tumors do not secrete PSA and laboratorial
follow-up should not constitute an isolated parameter in
these patients. BF is not synonymous of local recurrence in
the prostatic bed. It can be also due to distant metastases.
Moreover, a persistently elevated PSA serum level could be
also due to residual glandular healthy tissue in the post-
prostatectomy bed. Therefore, in patients with BF after
primary treatment, a diagnostic imaging procedure is often
carried out to distinguish between local cancer recurrence
and distant spread of disease [6]. Currently, in agreement
with literature data, the sensitivity (Se) and specificity (Spe)
of positron emission tomography/computed tomography
(PET/CT) using 11C-labeled or 18F-labeled Cho compounds
or the new radiotracer 68 Ga prostate-specific membrane
antigen 11, in restaging patients with PCa after primary
treatment, are greater in detecting metastatic lymph nodes,
distant metastases, and local neoplastic recurrences when
serum PSA values are41 ng/ml, PSA doubling time iso6
months, and PSA velocity is 42 ng/ml/y [7–10]. Although
PET/CT is recommended in patients with high PSA
serum values, in patients who experience low biochemical
alterations after RP (PSA serum values between 0.2 and
1 ng/ml) it is very important to exclude the presence of
locoregional recurrence, being this information essential for
radiation oncologists to target salvage treatment. To date,
the role of PET/CT in detecting local recurrence in
postprostatectomy bed or radiotreated prostate in patients
with BF and low PSA values is still incompletely defined,
probably because of the poor detection rate of small
lesions, which may be due to the limited spatial resolution
(5–6 mm) of PET scanners. mp-MRI—thanks to its inherent
superior contrast and spatial resolution, especially with an
endorectal coil—and the use of functional techniques,
represents an emerging and promising modality for the
evaluation of recurrent PCa after primary treatment [11].
The main mp-MRI findings after primary treatment are
summerised in the Table.Table
mp-MRI findings after prostate cancer primary treatment.
T2WI
Recurrent PCa after prostatectomy Slightly high signal in
Recurrent PCa after radiotherapy Low signal intensity
Recurrent PCa after focal therapies Low signal intensity
Fibrotic tissue Low signal intensity
Granulation tissue High signal intensity
Retained seminal vesicles High signal intensity
Residual glandular healthy tissue after prostatectmy High signal intensitymp-MRI: Technical aspects
Morphological T2WI is acquired with a high spatial
resolution technique (3–4 mm thickness) in order to identify
very small pathological tissues [12]. In DCEI the prostate
bed is repetitively acquired with a gradient-echo T1W
sequence before and after intravenous injection of contrast
medium over a period of time. DCEI, in addition to
qualitative assessment of the images, allows the calculation
of semiquantitative parameters such as peak enhancement,
time to peak, wash-out slope, area under the contrast
enhancement curve, and quantitative parameters, such as
Ktrans, Ve, and Kep [12]. PCa shows neoangiogenesis and
is, therefore, associated with early and high peak enhance-
ment, wash-out slope, high area under the contrast enhance-
ment curve, and higher Ktrans, Kep, and Ve.
DWI is based on an echo-planar sequence and depicts
the diffusivity of water molecules along the 3 space
directions within the tissue. It provides qualitative and
quantitative information about “cell density” and cell
membrane integrity. In neoplastic prostatic tissue extracel-
lular space is decreased; therefore, the movement of water
molecules is restricted and the so-called apparent diffusion
coefficient (ADC) values are low compared with healthy
prostatic tissue. DWI can be performed without the admin-
istration of exogenous contrast agent and it does not require
long acquisition times [13]. MRS imaging (MRSI) provides
3-dimensional data set of the prostate gland, with volume
voxels ranging from 0.24 cm to 0.34 cm. This functional
technique evaluates the relative concentration of metabolites
within voxels. The main metabolites in the prostate gland
are citrate (Cit, a marker of benign tissue), creatinine (Cr,
insignificant for diagnosis, but difficult to resolve from
choline), and choline (Cho, involved in the cellular mem-
brane synthesis and degradation, a marker of malignant
tissue). The peak integral ratio of Cho plus Cr to Cit
(CC/C ratio) can distinguish PCa tissue from healthy glandular
tissue. Conforming to the literature, in a nontreated prostate
gland, each voxel can be defined as follows: fibrotic or scar
tissue when the ratio is o0.2, residual healthy prostatic
glandular tissue when the ratio is between 0.2 and 0.5,
probably recurrent PCa when the ratio is between 0.5 and 1,
and definitely recurrent PCa tissue when the ratio is41 [14].DWI DCEI
tensity Restricted diffusion Rapid wash in and wash out
Restricted diffusion Rapid wash in and wash out
Restricted diffusion Rapid wash in and wash out
No restricted diffusion Slightly delayed enhancement
No restricted diffusion Mild or no enhancement
No restricted diffusion Delayed wash in and wash out
No restricted diffusion Mild or no enhancement
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When a post-RP BF is recognized, salvage RT is
generally performed without histological confirmation of
local relapse, as transrectal ultrasound (TRUS) is neither
sensitive nor specific and a negative biopsy does not rule
out a local recurrence [6]. With the development of
intensity-modulated RT and image-guided RT, there is the
potential to escalate the dose in areas of known disease
recurrence after RP, so that accurate identification of local
recurrence with pelvic imaging might improve the effec-
tiveness of tumor eradication, improving therefore the
chance of long term control [15]. mp-MRI represents an
emerging and promising modality for the evaluation of
prostatic fossa after RP. Moreover, mp-MRI after RP is a
very useful tool to discriminate between locoregional
relapse and small amount of residual glandular healthy
tissue, scar/fibrosis, retained seminal vesicle and granulation
tissue and it may even be able to assess the aggressiveness
of nodule recurrence by means of ADC values [10,11,16–18].
A recurrent PCa can be recognized as a soft tissue mass in the
surgical bed with slightly high T2 signal intensity (SI) than
the adjacent muscle, with restricted diffusion and rapid wash
in and wash out at DCEI (Fig. 1). The presence, on T2WI, of
a lobulated, semicircumferential, nodular-like, or plaque-like
soft tissue thickening in the prostatectomy bed that appear
slightly hyperintense compared to pelvic muscles should be
considered to be strongly suggestive of local recurrence [3].
The most common site of postoperative local recurrence is theFig. 1. Multiparametric-MR images of a 64-year-old man with prostate-specific a
prostatectomy, with suspected local recurrence. (A) Axial T2-weighted fast spin
perianastomotic location in front of the rectal wall at approximately 30 mm fro
muscles (white arrow). (B) Axial gradient-echo T1-weighted perfusion image sh
(C) Axial native DWI image at b ¼ 3,000 s/mm2 showing marked restricted diff
from images obtained at b ¼ 0, 500, 1,000, and 3,000 s/mm2 shows a dark are
images and hypervascular nodule seen on color map (black arrow). All these fi
available online.vesicourethral anastomosis around the urinary bladder or
membranous urethra [3]. Other common sites of local
recurrence are retrovesical (between the urinary bladder and
rectum), at the anterior or lateral surgical margins of the
prostatectomy bed (e.g., abutting the levator ani muscles) and
at the resection site of the vas deferens [19]. In most cases
local recurrence can be readily distinguished from normal
perianastomotic scar/fibrotic changes, which appears of low
SI compared with muscle on T2WI with no or slightly
delayed enhacement at DCEI. Granulation tissue may occa-
sionally be present in the perianastomotic region, where it can
mimic the appearance of tumor recurrence because of its high
SI relative to the pelvic muscles, however, it shows no or mild
enhancement on delayed contrast images at DCEI, whereas
local PCa recurrence shows early rapid contrast wash in
and wash out [20]. After RP retained SVs are observed in
approximately 20% of patients. Most retained SVs are
very low in SI because of fibrosis and may demonstrate
preservation of their convoluted tubular appearance. If a SV
shows an area of focally increased T2 SI it can mimic a
recurrence. The clue to distinguish retained SVs from
recurrent PCa is that retained SVs would not demonstrate
diffusion restriction or rapid contrast wash in and wash out
at DCEI [20].
The role for spectroscopy after RP remains controversial
and needs to be defined further. Indeed, spectroscopy is limited
by its poor spatial resolution and its high sensitivity to field
inhomogeneities and susceptibility artefacts caused by surgical
clips in the anastomotic area, which decrease the spectroscopicntigen progression (PSA serum level ¼ 0.65 ng/ml) after radical retropubic
-echo image shows a soft tissue nodule of 1 cm in size on posterior left
m the ureteral meatus, which is slightly hyperintense compared to pelvic
owing a remarkable enhancement of the pathological tissue (white arrow).
usion of water molecules (white arrow). (D) Axial ADC map reconstructed
a corresponding to the abnormal hyperintense tissue seen on T2-weighted
ndings are consistent with locoregional relapse. Color version of figure is
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ments. Nevertheless in case of larger lesions in the prostatec-
tomy fossa (410 mm) MRSI can play a role as problem
solving technique in doubtful cases when the other techniques
are borderline. A high Cho concentration in the lesion is more
suggestive of PCa recurrence than residual benign gland or
fibrosis [10,11]. Wu et al. [21] in a meta-analysis carried out to
assess the effectiveness of mp-MRI in detecting local recurrent
PCa after RP found that DCEI, compared with T2WI, showed
higher pooled Se (85%) and Spe (95%) and when combined
with MRSI had the highest pooled Se (92%). Panebianco et al.
[18] assessed the role of 3T-DWI in the detection of local PCa
recurrence analyzing a large number of patients (262 men) with
BF after RP. The patient population was divided into 2 groups
according to recurrent lesion size detected on MRI and PSA
serum level. Group A included 126 patients with PSA ranging
from 0.5 to 1.7 ng/ml and a lesion size ranging from 4 to
8 mm. Group B included 116 patients with PSA serum level
ranging from 1.4 to 2.9 ng/ml and a lesion size ranging from 9
to 15 mm. In group A, the presence of local disease was
ascertained on the basis of TRUS-guided biopsy, whereas in
group B a reduction of PSA serum values higher than 50%
following RT was used to validate mp-MRI results. For the
identification of local recurrence in group A, combined T2WI
and DCEI (T2 þ DCEI) displayed Se 98%, Spe 94%, positive
predictive values (PPV) 97%, negative predictive values (NPV)
96%, and accuracy of 93%; combined T2WI and DWI with a
b ¼ 3,000 mm2/s (T2 þ DW3) had Se 97%, Spe 95%, PPV
96%, NPV 95%, and accuracy of 92%; combined T2WI and
DWI with a b ¼ 1,000 mm2/s (T2 þ DW1) showed Se 93%,
Spe 89%, PPV 94%, NPV 91%, and accuracy of 88%. The
area under the receiver operating characteristic curve for
T2 þ dynamic contrast enhanced [DCE] was 0.917, for
T2 þ DW3 was 0.823, and for T2 þ DW1 was 0.724. In
group B T2 þ DCE had Se 100%, Spe 97%, PPV 96%, NPV
95%, and accuracy of 91%; T2 þ DW3 showed Se 98%, Spe
96%, PPV 93%, NPV 91%, and accuracy of 89%; T2 þ DW1
displayed Se 94%, Spe 92%, PPV 91%, NPV 89%, and
accuracy of 86%. The Az for T2 þ DCE was 0.875, for
T2 þ DW3 was 0.783, and for T2 þ DW1 was 0.679. The
authors supposed that the overall accuracy of DCEI is superior
to that of DWI because DWI are more affected by distortion
artefacts because of surgical clips and background noise than
DCEI are, though there are some cases in which DCEI is
doubtful and DWI is of paramount importance for local
recurrence depiction. For instance, a prominent periprostatic
venous plexus may sometimes mimic the appearance of
enhancing recurrent tumor on DCEI; therefore, when there is
this potential pitfall DWI is mandatory to exclude the presence
of abnormal tissue in the postprostatectomy bed. Moreover,
the authors in order to evaluate the aggressiveness of
local recurrent PCa, compared ADC values of locoregional
recurrences with the histological results. The mean and
standard deviation of ADC values were 0.5  0.23 mm2/s
for high-grade aggressiveness, 0.8  0.09 mm2/s for
intermediate-grade aggressiveness, and 1.1  1.17 mm2/s forlow-grade aggressiveness; ADC values higher than 1.3 mm2/s
(mean ADC ¼ 1.4; range: 1.3–1.7) were found in patients
with a histological finding of prostatic gland remnants.
Roy et al. [22] in a recent study evaluated the Se of the 3
types of functional MRI techniques in the detection of local
PCa recurrence after RP and after EBRT. They enrolled 60
consecutive patients with BF after RP or after EBRT.
TRUS-guided biopsy was used to validate MRI results.
The patient population was divided into 2 groups according
to the therapy delivered. Group A included 28 patients
(serum PSA value range: 0.3–2.8 ng/ml) who underwent
RP, and group B included 32 patients (PSA serum level
range: 2.2–4.8 ng/ml) who received EBRT. In group A the
Se was highest for T2WI plus DCE (97%) followed, in
decreasing order, by DCEI alone (94%) and T2WI plus
DWI plus DCEI (94%), T2WI plus DWI plus DCEI plus
MRSI (74%), DWI alone (65%) and T2WI plus DWI
(65%), T2WI alone (56%), T2WI plus MRSI (53%), and
lastly MRSI (50%). The worst results were obtained with
isolated T2WI and MRSI; the lower performance of MRSI
may reflect a partial volume effect due to the voxel size.
In patients scheduled for local salvage EBRT after RP,
accurate anatomic localization of tumor deposits within the
postprostatectomy bed, by means of mp-MRI, may allow
for an individualized field of irradiation, thereby max-
imizing efficacy and minimizing toxicity to normal sur-
rounding tissues. In this setting mp-MRI findings could be
used to apply a stereotactic boost to the recurrence site,
potentially improving in this way the control of local
disease and avoiding further locoregional relapses over
time. Furthermore, the differential diagnosis between resid-
ual glandular healthy tissue and locoregional neoplastic
recurrence is of paramount importance for the radiation
oncologist because the dose of RT delivered in the prostate
bed is quite different [23]. The recent development of the
new hybrid PET/MRI scanners, with simultaneous acquis-
ition of mp-MRI and PET images, can yield combined
structural, functional, and metabolic information that can
potentially affect patient management and outcome [24].
Cho-PET/MRI might improve RT planning by enabling
more precise target volume delineation of local recurrence
as well as of PCa involved lymph nodes [25].mp-MRI after EBRT
In patients with local recurrence after RT, if local salvage
therapy is not undertaken early, then the median time to
development of distant metastases is E3 years [26]. Local
salvage therapies with curative intent include additional
irradiation of the prostate, RP, and other new treatment
options such as cryosurgery, transrectal high-intensity focused
ultrasound trans-rectal ultrasonography guided (TRUS-
guided) and laser therapy [27]. As the exact location of the
recurrent tumor within the prostate is generally unknown, the
general practice of salvage therapies involves treatment of the
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imaging techniques able to identify and localize recurrent PCa
in order to perform focal salvage therapies effectively with
minimal complications.
At present mp-MRI is widely considered to be the state
of the art in detecting and localizing PCa recurrence in
patients with BP after definitive RT. After RT, the entire
prostate and the SVs show decreased size and diffusely
decreased SI on T2WI, and the peripheral, central, and
transition zones appear less distinct from each other
[28]. PCa also show changes, which may include decreased
size, reduced capsular bulging, capsular irregularity, or
decreased extracapsular extension. These changes are
caused by RT induced glandular atrophy and fibrosis.
The effects of RT on the T2WI appearance of adjacent
anatomic structures include increased bladder or rectal wall
thickness, thickening of the perirectal fascia, and increased
SI of the pelvic sidewall musculature [29]. In addition,
there may be increased SI in the bone marrow on T1WI
due to post-RT fatty replacement [29]. T2WI alone is of a
limited diagnostic accuracy because the recurrent tumor
and the normal surrounding parenchyma both appear
hypointense [12]. It has been hypothesized that cancer
can be detected under such circumstances if it produces an
additional focal reduction in SI [30] or if appears as a
hyperintense region compared to surrounding prostate
tissue [31]. Moreover, a focal T2 hypointense region mayFig. 2. A 64-year-old man with TRUS-guided biopsy-proved PCa of the left thi
images before EBRT showing a hypointense focus on the left third middle perip
images obtained after 14 months after external beam radiation therapy. (B) Axia
which appears diffusely hypointense because of radiation induced atrophy and fi
(C) Axial gradient-echo T1-weighted color map image showing a remarkable nod
DWI image at b ¼ 3,000 s/mm2 showing a focus with marked restricted diffusion
images obtained at b ¼ 0, 500, 1,000, and 3,000 s/mm2 shows a dark area corre
consistent with local recurrent PCa.represent the treated nonviable tumor and not necessarily
cancer recurrence [12].
A recurrent PCa tumor after EBRT is seen as an area,
commonly seen at the same location of the pretreatment
tumor, with diffusion restriction and rapid contrast wash in
and wash out at DCEI, usually isointense to the surrounding
parenchyma on T2WI (Fig. 2). Following RT even though
the gland is usually small and atrophyc, the anterior
fibromuscolar stroma may be hypertrophic with a mass like
appearance. The enlarged stroma has a low T2 SI due to
fibrotic content with diffusion restriction mimicking a
recurrence, but on DCEI it shows no enhacement [20].
Identifying a recurrent disease using DCEI is easier,
paradoxically, than the initial detection of cancer—this is
because of the very different patterns between recurrence
and postradiation fibrosis. After RT, recurrent tissue can be
recognized as hypervascular early enhancing homogeneous
nodule, whereas in the surrounding prostatic tissue the
enhancement is homogeneous, slow, and low [6]. Hence,
DCEI is more reliable than T2WI for the detection of
recurrent PCa. A serious drawback of DCEI is that its Spe
in depicting the recurrence in the central gland is almost
always reduced. Following RT hypertrophic nodules in the
central gland may be well preserved with little or no
radiation induced changes. These nodules usually show
restricted diffusion and rapid contrast wash in and wash out
mimicking recurrence. These nodules can be differentiatedrd middle peripheral zone (Gleason score, 3 þ 4). (A) Axial T2-weighted
heral zone corresponding to cancerous lesion. (B–E) Multiparametric-MR
l T2-weighted fast spin-echo image shows shrinkage of the prostate gland,
brosis with a hypointense focus in the same location of the treated cancer.
ular enhancement at the left third midgland (white arrow). (D) Axial native
of water molecules (white arrow). (E) Axial ADC map reconstructed from
sponding to the hypervascular nodule (white arrow). All these findings are
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different location from pretreatment tumor and contrast
enhacement similar to the central gland. DCEI should be
performed at least 3 months after RT because an increase in
perfusion and blood volume due to an inflammatory reaction
of the tissue to RT can be found immediately after treatment.
MRSI in evaluating the response to RT and in detecting local
recurrence yielded promising result. The use of an endorectal
coil is essential for spectroscopic imaging even at high field
strength, because it increases signal-to-noise ratio by a factor
of 10, which results in higher spatial and spectral resolution
[32]. Panebianco et al. [33] in a recent study showed that
MRSI follow-up, using CC/C ratio, shows a greater potential
compared to PSA in monitoring patients after EBRT because
MRSI can demonstrate PCa recurrence or residual disease
before the BR occurs, leading to the possibility to deliver
salvage local therapy, and thus the chance for cure as early as
possible. Wu et al. in a meta-analysis carried out to assess the
effectiveness of T2WI, DCEI, and MRSI in detecting local
recurrent PCa after EBRT found that DCEI, compared with
T2WI, showed higher pooled Se (90%) and Spe (81%).
DCEI combined with MRSI had the highest pooled Se and
Spe (90%) [21]. Furthermore, a comparison of pre-EBRT
and post-EBRT MRI has shown that most recurrent cancers
occurred at the site of primary tumors [34].
Local PCa recurrence appears as an area of high SI on
DWI native images and of low SI on ADC maps relative to
the surrounding healthy prostate tissue. Many false-positive
can occur. Similar findings may be observed in various
benign conditions of the prostate, including hemorrhage,
hyperplasia, adenoma, and chronic inflammation. Postbiopsy
hemorrhage has been also reported to reduce ADC values
[35]. In a recent study, Donati et al. [36] analyzed a patient
population of 53 men with BR after EBRT. TRUS-guided
biopsy was used as the standard of reference. They showed
that in detecting recurrent tumor the addition of DCEI to
T2WI plus DWI did not improve diagnostic accuracy, thus
eliminating the risks and costs associated with the intravenous
administration of gadolinium-based contrast agents. Roy et al.
[22] in a recent study evaluated the Se in the detection of
post-RT local PCa recurrence of the 3 types of functional
MRI techniques, with TRUS-guided biopsy as the standard of
reference. They enrolled 32 patients with BR after EBRT
(PSA serum level range: 2.2–4.8 ng/ml). The Se was highest
for T2WI plus DWI plus DCEI plus MRSI (100%) followed
by, in decreasing order, T2WI plus DWI, DCEI alone and
DWI alone (94%), T2WI plus DCEI (91%), T2WI plus DWI
plus DCEI plus MRSI (76%), T2WI and MRSI alone (74%),
and lastly T2WI plus MRSI (44%).mp-MRI after transperineal brachytherapy
BT is a type of RT in which the radiation source is
placed near or inside the treatment area. This technique
could be TRUS or MRI guide. A large number of 125I or192Ir seeds are implanted in the prostate via transperineally
inserted catheters. There is no consensus on BF after BT. A
PSA bounce, defined as a temporary increase of the PSA
level followed by a further decrease, occurs in 30% to 60%
of patients 12 to 24 months after implantation, without
clinical relevance. PSA bounce typically persists for
approximately 12 months and PSA levels usually do not
increase more than 1.0 ng/ml [6]. BT may produce several
levels of magnetic susceptibility artefacts on both morpho-
logical and functional sequences, hampering cancer detec-
tion. When visible, BT seeds appear as dark dots on T2WI
and ADC map. Similarly to EBRT, post-BT prostate tends
to appear diffusely hypointense on T2WI, with loss of the
normal zonal anatomy. BT seeds are often seen outside the
gland, in the surrounding fat planes and less commonly at
the base of the penis. According to Rouvière et al. [6],
recurrent foci may be identified on DCEI as early-enhanced
nodules. The use of DWI and MRSI is not well established
in the detection of intraglandular recurrence after BT mainly
due to local artefacts [37].mp-MRI after focal therapies
RP and EBRT can lead to significant complications, such
as incontinence and impotence, and can have a substantial
effect on quality of life. Consequently, promising techni-
ques such as cryosurgery, high-intensity focused ultrasound,
and laser-induced thermal therapy have emerged as feasible
minimally invasive focal treatment options able to preserve
uninvolved prostatic tissue with the aim of preserving
genitourinary function [38]. Focal therapy is controversial
as PCa is multifocal in approximately 70% to 80% of
patients [39]. However, it is the largest tumor focus (index
tumor) that is, presumed to be the main factor for tumor
progression and prognosis [40]. There are no validated
criteria for BF after focal therapies. Some centers consider a
PSA cutoff of around 1 ng/ml, which may be combined
with a posttreatment biopsy [6,41]. At the site of focal
treatment a heterogenous but low T2 SI may be seen with
no contrast enhancement. Data in literature are scarce
regarding PCa recurrence after focal therapies. Residual or
recurrent PCa following focal therapies exhibits a mass
effect along the edge of the previous treatment, with low T2
SI, diffusion restriction and rapid contrast wash in and
wash out.Conclusions
mp-MRI could be currently considered as the most
reliable imaging tool to detect local PCa recurrence in
patients with BF after primary treatment. mp-MRI after RP
is indicated to diagnose small local cancer recurrence in a
range of PSA serum values between 0.2 and 1 ng/ml
when PET/CT is not eligible. Moreover, mp-MRI, thanks
to functional techniques, allows the differentiation between
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granulation tissue, and tumor recurrence and it may also
be able to assess the aggressiveness of nodule recurrence.
Moreover, the recent development of hybrid PET/MRI
scanners could improve the diagnostic accuracy in depicting
local PCa relapses in postprostatectomy fossa. mp-MRI
findings could be used to boost the dose of salvage RT to
the recurrent PCa nodule and potentially improve the
control of local disease, thus avoiding an eventual locore-
gional relapses. The precise detection and localization of
local tumor recurrence after EBRT are of utmost importance
for following purposes: (1) for guiding targeted TRUS-
guided biopsy of suspicious areas, thus reducing the false-
negative rate associated with systematic biopsies, (2) to
perform MR-guided biopsy leading to a higher detection
rate of recurrent PCa with a minimum number of biopsy
cores compared to TRUS-guided systemic biopsies and,
consequently, leading to higher patient satisfaction, (3)
appropriate treatment selection and planning, (4) to guide
surgery, and (5) to improve the targeting of salvage RT
(external beam or interstitial) or minimally invasive ablative
techniques in order to perform focal salvage therapies
effectively with minimal complications. To minimize time
for mp-MRI data acquisition, we hypothesize that a
combination of T2WI and DWI could be sufficient to detect
local recurrence. This observation derives from the evidence
that DWI and DCEI are similar in terms of Se and accuracy
for recurrent PCa detection and localization both after RP
and EBRT [18,36]. Therefore, as DWI requires a short
imaging time, without the need for intravenous contrast
medium and has relatively simple postprocessing require-
ments, it could be assumed to be a valid alternative to DCE.
However, DCEI can be helpful in patients with seed
placement after BT, as DWI is prone to susceptibility
artifacts and distortion in these cases. mp-MRI in detecting
locoregional relapse after focal therapies in not yet inves-
tigated and need further studies in order to confirm its role.
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